---
document_datetime: 2025-12-29 09:23:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari.html
document_name: vantobra-previously-tobramycin-pari.html
version: success
processing_time: 0.1102168
conversion_datetime: 2025-12-30 01:36:44.205272
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vantobra (previously Tobramycin PARI)

[RSS](/en/individual-human-medicine.xml/67178)

##### Authorised

This medicine is authorised for use in the European Union

tobramycin Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vantobra (previously Tobramycin PARI)](#news-on)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vantobra is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis.

Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections. P. aeruginosa is a frequent cause of infections in cystic fibrosis patients.

Vantobra is a 'hybrid medicine'. This means that it is similar to a 'reference medicine' containing the same active substance, tobramycin; however, Vantobra has a higher amount of the active substance. The reference medicine for Vantobra is Tobi.

Expand section

Collapse section

## How is Vantobra used?

Vantobra is available as a nebuliser solution in single-dose 'ampoules'. It can only be obtained with a prescription.

Vantobra is inhaled using a device called Tolero nebuliser, which converts the solution in the ampoule into a fine mist.

The recommended dose is one ampoule twice a day, ideally 12 hours apart. After a 28-day course of treatment, the patient stops treatment for 28 days, before starting another 28-day course. Treatment courses may be repeated for as long as the doctor considers the patient to be benefiting from treatment.

If the patient is also receiving other inhaled treatments or chest physiotherapy, it is recommended that Vantobra is used last. For more information about using Vantobra, see the package leaflet or contact your doctor or pharmacist.

## How does Vantobra work?

The active substance in Vantobra, tobramycin, belongs to the group of antibiotics known as 'aminoglycosides'. It works by interfering the production of proteins that P. aeruginosa needs to build its cell walls, resulting in damage to the bacteria, which eventually kills them.

## What benefits of Vantobra have been shown in studies?

Tobramycin has been used for several years to treat P. aeruginosa infection in patients with cystic fibrosis and the applicant submitted data from the literature to support the use of Vantobra.

In addition, a 'bioequivalence' study in 58 patients with cystic fibrosis aged 6 years and above determined whether Vantobra produces similar levels of the active substance in the body as the reference medicine, Tobi. The results of the study showed that Vantobra can be considered comparable to Tobi.

## What are the risks associated with Vantobra?

Side effects with Vantobra are not common. However, the following side effects are seen in up to 1 in 100 patients: dyspnoea (difficulty breathing), dysphonia (hoarseness), pharyngitis (sore throat) and cough. For the full list of side effects and restrictions, see the package leaflet.

## Why is Vantobra authorised in the EU?

The European Medicines Agency decided that Vantobra's benefits are greater than its risks and it can be authorised for use in the EU. The Agency noted that inhaled tobramycin was the 'gold standard' for treating P. aeruginosa infection in patients with cystic fibrosis and that some patients cannot use the dry powder form because of unacceptable side effects. For these patients Vantobra, which is inhaled as a solution from a nebuliser, would be a useful alternative.

In addition, it takes less time to inhale Vantobra than other tobramycin nebulisers and the time it takes is comparable to the time it takes to inhale the dry powder. Vantobra is therefore easier to use and might help patients to stick to their treatment.

The Agency noted that safety profile of inhaled tobramycin was well known. There were no unexpected safety issues with Vantobra.

## What measures are being taken to ensure the safe and effective use of Vantobra?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vantobra have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vantobra are continuously monitored. Side effects reported with Vantobra are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vantobra

Vantobra received a marketing authorisation valid throughout the EU on 19 February 2019.

Vantobra : EPAR - Medicine overview

Reference Number: EMA/467446/2019

English (EN) (119.27 KB - PDF)

**First published:** 17/04/2019

**Last updated:** 28/08/2019

[View](/en/documents/overview/vantobra-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-567)

български (BG) (164.22 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/bg/documents/overview/vantobra-epar-medicine-overview_bg.pdf)

español (ES) (139.26 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/es/documents/overview/vantobra-epar-medicine-overview_es.pdf)

čeština (CS) (161.02 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/cs/documents/overview/vantobra-epar-medicine-overview_cs.pdf)

dansk (DA) (138.44 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/da/documents/overview/vantobra-epar-medicine-overview_da.pdf)

Deutsch (DE) (142.81 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/de/documents/overview/vantobra-epar-medicine-overview_de.pdf)

eesti keel (ET) (135.79 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/et/documents/overview/vantobra-epar-medicine-overview_et.pdf)

ελληνικά (EL) (173.35 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/el/documents/overview/vantobra-epar-medicine-overview_el.pdf)

français (FR) (141.46 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/fr/documents/overview/vantobra-epar-medicine-overview_fr.pdf)

hrvatski (HR) (158.64 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/hr/documents/overview/vantobra-epar-medicine-overview_hr.pdf)

italiano (IT) (118.4 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/it/documents/overview/vantobra-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (174.33 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/lv/documents/overview/vantobra-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (139.65 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/lt/documents/overview/vantobra-epar-medicine-overview_lt.pdf)

magyar (HU) (159.06 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/hu/documents/overview/vantobra-epar-medicine-overview_hu.pdf)

Malti (MT) (161.29 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/mt/documents/overview/vantobra-epar-medicine-overview_mt.pdf)

Nederlands (NL) (141.2 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/nl/documents/overview/vantobra-epar-medicine-overview_nl.pdf)

polski (PL) (162.96 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/pl/documents/overview/vantobra-epar-medicine-overview_pl.pdf)

português (PT) (140.57 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/pt/documents/overview/vantobra-epar-medicine-overview_pt.pdf)

română (RO) (114.83 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/ro/documents/overview/vantobra-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.06 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/sk/documents/overview/vantobra-epar-medicine-overview_sk.pdf)

slovenščina (SL) (156.16 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/sl/documents/overview/vantobra-epar-medicine-overview_sl.pdf)

Suomi (FI) (136.16 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/fi/documents/overview/vantobra-epar-medicine-overview_fi.pdf)

svenska (SV) (137.17 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

28/08/2019

[View](/sv/documents/overview/vantobra-epar-medicine-overview_sv.pdf)

Vantobra (previously Tobramycin PARI) : EPAR - Risk-mangement-plan summary

English (EN) (30.29 KB - PDF)

**First published:** 17/04/2019

[View](/en/documents/rmp-summary/vantobra-previously-tobramycin-pari-epar-risk-mangement-plan-summary_en.pdf)

## Product information

Vantobra : EPAR - Product information

English (EN) (193.71 KB - PDF)

**First published:** 17/04/2019

**Last updated:** 13/12/2023

[View](/en/documents/product-information/vantobra-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-118)

български (BG) (335.34 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/bg/documents/product-information/vantobra-epar-product-information_bg.pdf)

español (ES) (194.18 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/es/documents/product-information/vantobra-previously-tobramycin-pari-epar-product-information_es.pdf)

čeština (CS) (295.74 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/cs/documents/product-information/vantobra-epar-product-information_cs.pdf)

dansk (DA) (384.14 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/da/documents/product-information/vantobra-epar-product-information_da.pdf)

Deutsch (DE) (403.98 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/de/documents/product-information/vantobra-epar-product-information_de.pdf)

eesti keel (ET) (233.78 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/et/documents/product-information/vantobra-epar-product-information_et.pdf)

ελληνικά (EL) (325.15 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/el/documents/product-information/vantobra-epar-product-information_el.pdf)

français (FR) (225.01 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/fr/documents/product-information/vantobra-epar-product-information_fr.pdf)

hrvatski (HR) (288.77 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/hr/documents/product-information/vantobra-epar-product-information_hr.pdf)

íslenska (IS) (568.29 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/is/documents/product-information/vantobra-previously-tobramycin-pari-epar-product-information_is.pdf)

italiano (IT) (391.59 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/it/documents/product-information/vantobra-epar-product-information_it.pdf)

latviešu valoda (LV) (318.84 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/lv/documents/product-information/vantobra-epar-product-information_lv.pdf)

lietuvių kalba (LT) (304.48 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/lt/documents/product-information/vantobra-epar-product-information_lt.pdf)

magyar (HU) (316.97 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/hu/documents/product-information/vantobra-epar-product-information_hu.pdf)

Malti (MT) (333.85 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/mt/documents/product-information/vantobra-epar-product-information_mt.pdf)

Nederlands (NL) (218.93 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/nl/documents/product-information/vantobra-epar-product-information_nl.pdf)

norsk (NO) (185.59 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/no/documents/product-information/vantobra-epar-product-information_no.pdf)

polski (PL) (311.61 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/pl/documents/product-information/vantobra-epar-product-information_pl.pdf)

português (PT) (201.29 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/pt/documents/product-information/vantobra-epar-product-information_pt.pdf)

română (RO) (561 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/ro/documents/product-information/vantobra-epar-product-information_ro.pdf)

slovenčina (SK) (304.82 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/sk/documents/product-information/vantobra-epar-product-information_sk.pdf)

slovenščina (SL) (291.36 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/sl/documents/product-information/vantobra-epar-product-information_sl.pdf)

Suomi (FI) (214.5 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/fi/documents/product-information/vantobra-epar-product-information_fi.pdf)

svenska (SV) (434.74 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

13/12/2023

[View](/sv/documents/product-information/vantobra-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/10 14/10/2023

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vantobra (previously Tobramycin PARI) : EPAR - All authorised presentations

English (EN) (11.49 KB - PDF)

**First published:** 17/04/2019

**Last updated:** 16/08/2019

[View](/en/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-618)

български (BG) (36.67 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/bg/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_bg.pdf)

español (ES) (13.25 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/es/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_es.pdf)

čeština (CS) (31.43 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/cs/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (11.21 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/da/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (11.26 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/de/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (11.37 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/et/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (34.55 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/el/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_el.pdf)

français (FR) (12.91 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/fr/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.34 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/hr/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (12.9 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/is/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_is.pdf)

italiano (IT) (12.96 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/it/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (33.53 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/lv/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (33.42 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/lt/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (20.86 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/hu/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (35.28 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/mt/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (12.99 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/nl/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (11.32 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/no/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_no.pdf)

polski (PL) (31.27 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/pl/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_pl.pdf)

português (PT) (13.15 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/pt/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_pt.pdf)

română (RO) (31.35 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/ro/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (32 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/sk/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (29.14 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/sl/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (11.39 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/fi/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.04 KB - PDF)

**First published:**

17/04/2019

**Last updated:**

16/08/2019

[View](/sv/documents/all-authorised-presentations/vantobra-previously-tobramycin-pari-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vantobra (previously Tobramycin PARI) Active substance tobramycin International non-proprietary name (INN) or common name tobramycin Therapeutic area (MeSH)

- Respiratory Tract Infections
- Cystic Fibrosis

Anatomical therapeutic chemical (ATC) code J01GB01

### Pharmacotherapeutic group

Antibacterials for systemic use

### Therapeutic indication

Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/005086 Marketing authorisation holder

Pari Pharma GmbH

Moosstrasse 3

Marketing authorisation issued 18/02/2019 Revision 6

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vantobra (previously Tobramycin PARI) : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (110.33 KB - PDF)

**First published:** 16/08/2019

**Last updated:** 13/12/2023

[View](/en/documents/procedural-steps-after/vantobra-previously-tobramycin-pari-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Vantroba (previously Tobramycin PARI)-H-C-PSUSA-00010370-202209 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/358219/2023

English (EN) (102.75 KB - PDF)

**First published:** 04/08/2023

[View](/en/documents/scientific-conclusion/vantroba-previously-tobramycin-pari-h-c-psusa-00010370-202209-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Vantobra (previously Tobramycin PARI) : EPAR - Public assessment report

Adopted

Reference Number: EMA/901707/2018

English (EN) (797.17 KB - PDF)

**First published:** 17/04/2019

[View](/en/documents/assessment-report/vantobra-previously-tobramycin-pari-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Tobramycin PARI

Adopted

Reference Number: EMA/CHMP/862388/2018

English (EN) (197.84 KB - PDF)

**First published:** 14/12/2018

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-tobramycin-pari_en.pdf)

#### News on Vantobra (previously Tobramycin PARI)

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 December 2018](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018) 14/12/2018

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/12/2023

## Share this page

[Back to top](#main-content)